Page 30 - Read Online

Page 8 of 8 Bourinbaiar et al. Hepatoma Res 2020;6:2 I http://dx.doi.org/10.20517/2394-5079.2019.25

6. Longo V, Brunetti O, Gnoni A, Licchetta A, Delcuratolo S, et al. Emerging role of immune checkpoint inhibitors in hepatocellular
carcinoma. Medicina (Kaunas) 2019;55:E698.
7. Tarakanovskaya MG, Chinburen J, Batchuluun P, Munkhzaya C, Purevsuren G, et al. Open-label Phase II clinical trial in 75 patients
with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. J Hepatocell
Carcinoma 2017;4:59-69.
8. Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS. Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5)
vaccine in patients with chronic hepatitis C. Vaccine 2008;26:2733-7.
9. Batdelger D, Dandii D, Dahgwahdorj Y, Erdenetsogt E, Oyunbileg J, et al. Clinical experience with therapeutic vaccines designed for
patients with hepatitis. Curr Pharm Des 2009;15:1159-71.
10. Bourinbaiar AS, Mezentseva MV, Butov DA, Nyasulu PS, Efremenko YuV, et al. Immune approaches in tuberculosis therapy: a brief
overview. Exp Rev Anti-infect Ther 2012;10:381-9.
11. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
12. Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Lett 2019;470:8-17.
13. Baradaran Noveiry B, Hirbod-Mobarakeh A, Khalili N, Hourshad N, Greten TF, et al. Specific immunotherapy in hepatocellular
cancer: a systematic review. J Gastroenterol Hepatol 2017;32:339-51.
14. Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha fetoprotein DNA prime and adenovirus boost immunization of two
hepatocellular cancer patients. J Transl Med 2014;12:86.
15. Nobuoka D, Yoshikawa T, Sawada Y, Fujiwara T, Nakatsura T. Peptide vaccines for hepatocellular carcinoma. Hum Vaccin
Immunother 2013;9:210-2.
16. Buonaguro L; HEPAVAC Consortium. Developments in cancer vaccines for hepatocellular carcinoma. Cancer Immunol Immunother
2016;65:93-9.
17. Shen L, Zhang J, Lee H, Batista MT, Johnston SA. RNA transcription and splicing errors as a source of cancer frameshift neoantigens
for vaccines. Sci Rep 2019;9:1-3.
18. Silin DS, Lyubomska OV, Jirathitikal V, Bourinbaiar AS. Oral vaccination: where we are? Expert Opin Drug Deliv 2007;4:323-40.
19. Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, et al. MHC-II neoantigens shape tumour immunity and response to
immunotherapy. Nature 2019:574:696-701.
20. Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, et al. Angiogenesis and immune checkpoint inhibitors as therapies for
hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer 2019;7:333.
21. Rafei H, Mehta RS, Rezvani K. Editorial: cellular therapies in cancer. Front Immunol 2019;10:2788.